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Abstract Several (pre-) clinical trials are currently investigat-
ing the benefit of HER2-targeted therapy in urothelial bladder
cancer (UBC). Patients with HER2 amplified UBC could poten-
tially profit from these therapies. However, little is known about
histomorphology, HER2 protein expression patterns and oc-
currence of alterations in the HER2 gene in their tumors.
Among 150 metastasizing primary UBC, 13 HER2 amplified
tumors were identified. Their histopathological features were
compared with 13 matched, non-amplified UBC. HER2 pro-
tein expression was determined by immunohistochemistry.
The 26 tumors were screened for mutations in exons 19 and
20 of the HER2 gene. UBC withHER2 amplification present-
ed with a broad variety of histological variants (median 2 vs.
1), frequently featured micropapillary tumor components
(77 % vs. 8 %) and demonstrated a high amount of tumor
associated inflammation. Immunohistochemically, 10 of 13
(77 %) HER2 amplified tumors were strongly HER2 protein
positive. Three tumors (23 %) were scored as HER2 negative.
One of the HER2 amplified tumors harbored a D769N muta-
tion in exon 19 of theHER2 gene; all other tested tumors were
wild type. In conclusion, HER2 amplified UBC feature specific
morphological characteristics. They frequently express the
HER2 protein diffusely and are, therefore, promising candidates
for HER2 targeted therapies. The detection of mutations at the
HER2 locusmight add new aspects tomolecular testing ofUBC.
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Introduction
The human epidermal growth factor receptor 2 (HER2/neu,
erbB2) constitutes, together with HER1 (EGFR, erbB1),
HER3 (erbB3), and HER4 (erbB4), the type I group of 20
families of receptor tyrosine kinases. HER2 is a transmem-
brane 185 kDa protein; its encoding gene is on chromosome
17q21 [1]. The orphan HER2 without known ligand acts as
co-receptor for heterodimer formations with the other EGFR
family members [2]. These receptor heterodimers are drivers
of cellular proliferation [3], inhibit apoptosis [4], and promote
angiogenesis [5].
HER2 overexpression characterizes particularly aggressive
cancer types of various origin that share poor outcome [6].
Originally detected in a subset of breast cancer [7], amplifica-
tion of the HER2 gene is the primary mechanism for protein
overexpression [8]. At present, targeted anti-HER2 therapies
are established clinical routine for HER2 overexpressing/
amplified carcinomas of the breast [9] and stomach [10].
Recent works have evaluated HER2 status in urothelial blad-
der cancer (UBC) in order to assess the therapeutic potential of
this target, demonstrating significant protein overexpression
(score 2+ or 3+) or gene amplification in approximately
10 % of the tumors [11–15]. In addition, several phase II
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and even phase III trials are currently investigating the possi-
ble benefit of HER2 targeted therapies for patients with UBC
(http://clinicaltrials.gov: NCT00151034, NCT00004856,
NCT00005831. https://www.clinicaltrialsregister.eu:
EudraCT: 2007-001826-28).
Considering these developments, pathologists will presum-
ably have to identify UBC with HER2 amplification for per-
sonalized treatment in the nearer future. As only little is
known about the histomorphology of these cases, better
knowledge hereof might facilitate their identification.
Morphological preselection before accomplishing additional
examinations by immunohistochemistry or molecular proce-
dures may even be interesting from an economical point of
view. Finally, HER2 expression of amplified UBC has not
been described in detail and the presence of additional muta-
tions is largely unknown. We evaluated these open questions
in a high-risk cohort of advanced metastasizing UBC.
Methods
Patients
Our cohort comprised of 150 bladder cancer patients (29 fe-
males and 121 males) treated by standardized, extended bilat-
eral pelvic lymphadenectomy with cystectomy as a single pro-
cedure at the Department of Urology, University Hospital of
Bern, Switzerland. No neoadjuvant therapy was given.
Median age at surgery was 67 years (range 35–89); most prima-
ry tumors were advanced (pT1, n=4; pT2, n=17; pT3, n=92;
and pT4, n=37).
Pathological techniques
The opened bladder specimens were fixed overnight in neutral
buffered formalin and processed at the Institute of Pathology,
University of Bern. The tumor samples tested for molecular
alterations were collected in accordance with the required in-
ternational ethical guidelines including approval by the
Institutional Review Board at the Institute of Pathology,
University of Bern.
Identification of HER2 amplified and non-amplified cancers
ATMAwith the 150 UBC was constructed and evaluated for
HER2 amplification by fluorescence in situ hybridization.
These results were published previously [12]. In the current
study, the 13 amplified tumors (HER2/CEP17 ratio≥2.2 [16])
were further investigated and their histopathological charac-
te r i s t ics compared wi th 13 non-ampl i f ied UBC
(HER2/CEP17 ratio<1.8; [16]) from our cohort, matched by
age, pT stage, and operation date.
Morphological evaluation
All HER2 amplified and non-amplified urothelial carcinomas
were evaluated by two independent investigators (JT and AF)
for numbers and percentage of histomorphological variants
[17] present in the tumors and the final result was formulated
as a consensus. These numbers and percentages in each sub-
group were added up for comparison. The amount of tumor-
associated inflammation was graded from a score zero to three
(negative, mild, moderate, and strong) for each case based on
the spectrum observed over all tumors.
Immunohistochemistry and in situ hybridization
Immunohistochemistry for the detection of HER2 expression
was performed on one representative cross sectional slide per
tumor, displaying a maximum of tumor tissue mass. The orig-
inal HercepTest (DAKO, Glostrup Denmark) was used for
immunohistochemical stains which were performed according
to the manufacturer’s protocol. HER2 protein expression per
cross sectional slide was classified according to the modified
DAKO criteria [16]: negative (0/1+), weakly positive (2+),
and positive (3+) with a cut-off for score 3+ for a more than
30% strong complete membranous staining of the tumor cells.
For comparison of Her2 protein phenotype and amplifica-
tion status, dual in situ hybridization (ISH) was performed on
one large section. The HER2 gene is detected by a
dinitrophenyl (DNP) labeled probe and visualized utilizing
VENTANA ultraView Silver ISH DNP (black signals)
Detection. The chromosome 17 centromere is targeted with
a digoxigenin (DIG) labeled probe and detected using VENT
ANA ultraView Red ISH DIG detection (red signals).
Detailed instructions for hybridization procedures are provid-
ed by the manufacturer.
HER2 mutation analysis
Genomic DNAwas obtained from all amplified tumor tissues
by overnight digestion with proteinase K at 55 °C followed by
DNA extraction using the BioRobot EZ1 workstation
(Qiagen). Intron-based primers were used to amplify exon
19 and 20 encompassing the main hot spot of activating mu-
tations of theHER2 gene [18, 19]. The primer sequences were
as follows: forward primer exon 19, 5′-CCCACGCTCTTC
TCACTCAT-3′; reverse primer exon 19; 5′-TCCTTCCTGT
CCTCCTAGCA-3′; forward primer exon 20, 5′-TGGTCTCC
CATACCCTCTCA-3′; and reverse primer exon 20, 5′-CAAA
GAGCCCAGGTGCATA-3′. Sequence analysis was per-
formed using the 3500 genetic analyzer (Applied
Biosystems). In addition, exon 20 was analyzed for in-
frame-insertions by capillary electrophoresis using a 6-
carboxy-fluorescine labeled forward primer and the same
reverse primer.
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Results
Morphological features of HER2 amplified
and non-amplified urothelial bladder cancer
A hallmark of the HER2 amplified tumor group was
micropapillary growth, which was present in 10 out of 13
cases (77 %): three tumors (23 %) were purely (100 %), one
tumor (8%) extensively (80 %), and six tumors (46 %) focally
(up to 10 %) micropapillary. When related to the entire tumor
mass within the HER2 amplified group, the micropapillary
proportion accounted for 32.7 % of this tumor mass
(Figs. 1a, b and 3). HER2 amplified tumors often pre-
sented with components of UBC variants (median 2 per
tumor) including the nested variant (Fig. 1c), two tu-
mors (15 %) were composed of three different compo-
nents. Finally, tumor-associated inflammation was high
(mean score 1.9) and showed both intratumoral and
peritumoral infiltrates (Fig. 1d).
In contrast, the HER2 non-amplified group showed mostly
conventional UBC: nine tumors (69 %) were purely
(100 %) and three tumors (23 %) were extensively
(60–70 %) of this type (Fig. 2a). One tumor (8 %) featured a
purely sarcomatoid growth pattern (100 %, Fig. 2b) with ac-
companying urothelial carcinoma in situ and one (8 %) had
micropapillary components (40 % of the otherwise conven-
tional UBC), which accounted for 3 % of the total tumor mass
in this group. Moreover, tumor-associated inflammation
(mean score 1.2) was scarce compared to the amplified group.
The trend for more monophasic growth in HER2 non-
amplified compared to HER2 amplified tumors was
reflected in a lower median number of morphologically
different tumor components per tumor (1 vs. 2 in the HER2
amplified group) and the absence of tumors with more than
two components.
Immunohistochemistry and ISH of HER2 amplified UBC
Ten out of the thirteen HER2 amplified tumors (77 %) were
scored as strongly HER2 positive (3+), out of which six tu-
mors (46 %) resulted in 100 %, two tumors (15 %) in 95 %,
one tumor (8 %) in 60 %, and one tumor (8 %) in 50 % strong
and complete membranous staining (Fig. 4a, b). Interestingly,
we infrequently noted a mosaic HER2 expression pattern
Fig. 1 HER2 amplified urothelial bladder cancers often show
micropapillary morphology (a, b HE×10 and×40) throughout the tumor or
together with other components like the nested variant (c HE×20). HER2
amplified urothelial bladder cancer often presents with marked
tumor-associated chronic inflammation (d HE×20)
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within overall HER2 expressing tumors scored as 3+ (Fig. 3).
Positive cells were found adjacent to negative or incompletely
stained cells in alternating patterns (Fig. 4c). No differences in
staining intensities were noted between morphological diverse
components and also not between superficial and deep parts of
these tumors.
There were no HER2 2+ but three (23 %) HER2 negative
tumors: one case (8 %) was scored as 1+ with a 50 % weak,
incomplete membranous staining and two score 0 cases
(15 %) with incomplete weak membranous immunohisto-
chemical reaction in less than 10 % of the tumor cells.
Two cases comprised areas of carcinoma in situ where we
noted a strong immunohistochemical reaction throughout the
lesion (Fig. 4d).
We reassessed the relation of HER2 protein overexpression
and amplification status on two consecutive large sections.
The immunostain showed 100 % strongly positive neoplastic
cells (score 3+) and the dual ISH stain presented HER2 am-
plification in all cancer cells (Fig. 5).
HER2 mutation analysis
The exons 19 and 20 of the HER2 gene were sequenced in all
HER2 amplified and non-amplified tumors to assess if some
of them contain activating mutations within these regions.
None of the tumors contained a mutation in exon 20.
However, one HER2 amplified tumor harbored a D769N mu-
tation (c.2305G>A) in exon 19 (Fig. 6). This mutation is
located in the αC helix of the catalytic domain of the enzyme.
Discussion
Specific genetic alterations in cancers may be associated with
particular morphological features as shown in colon and pros-
tate cancer [20, 21]. In UBC, there is currently only one com-
parable investigation. Ching et al. [22] evaluated the particu-
larly aggressivemicropapillary variant of urothelial carcinoma
for HER2 aberrations [22] and demonstrated HER2 protein
overexpression (score 2+ or 3+) in 68 % and HER2 gene
Fig. 3 Comparison of HER2
amplified and non-amplified
urothelial bladder cancers
(n=13 each) in regard to their
morphology (the tumor
components are given as
percentage in relation to the total
tumor mass in each group):
micropapillary architecture is
a key feature of HER2 amplified
urothelial bladder cancer
Fig. 2 HER2 non-amplified urothelial bladder cancers mostly show
conventional solid morphology (a HE×10); b sarcomatoid variant
(HE×20)
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amplification in 42 % of their 20 tumors. However, the
micropapillary variant with a prevalence of 0.6–6 % is rare
in UBC [17, 22, 23], and in general, a component of a con-
ventional UBC. As yet, the morphological spectrum of UBC
with HER2 amplification, which is an aggressive and from a
therapeutic point of view a potentially distinct subgroup, has
not been described. Better knowledge about its morphology
might help to better identify these tumors. Therefore, we first
identified HER2 amplified UBC in our cohort of high-risk,
metastasizing tumors and subsequently described their mor-
phology and HER2 expression patterns.
Micropapillary tumor growth was present in 77 % of our
HER2 amplified tumors; 31 % were purely or predominantly
micropapillary UBC, the residual tumors had minor
micropapillary fractions. The proportion of micropapillary
growth in relation to the entire tumor mass in this group was
33 %. This contrasts significantly with the HER2 non-
amplified UBC group, in which micropapillary growth was
present in only one tumor and this component occupied just
3 % of the entire evaluated tumor mass in this group. In addi-
tion, the HER2 amplified tumors presented with a significant-
ly higher morphological heterogeneity than the control group,
reflected by a higher number of subtype components per tu-
mor, and showed a significantly higher tumor-associated
chronic inflammatory infiltrate. Interestingly, the latter is in
line with a recent study showing that HER2 overexpression
activates multiple inflammatory pathways, especially NF-κB,
which is critical to Interleukin-6 (Il-6) expression [24].
Whether or not a relationship exists with the more recently
described association of polyoma virus with micropapillary
Fig. 4 HER2 immunohistochemistry: a strong membranous positivity in 100 % of the tumor cells of a conventional urothelial bladder cancer, score 3+;
b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium
Fig. 5 In situ hybridization showing Her2 amplification in 100 % of the
neoplastic urothelial bladder cancer cells (HER2 gene=black, centromere
17=red)
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UBC needs further investigation [25, 26]. Taken together, the-
se histomorphological features of HER2 amplified UBC—
frequent micropapillary architecture, morphological het-
erogeneity and marked tumor-associated chronic inflam-
mation—allow pathologists to better identify this clinical-
ly important, particularly aggressive subset of UBC [12]
and herewith to contribute to enhanced survival prediction
and preselection for potential anti-HER2 therapies in the future.
Only few studies have investigated HER2 amplification
and overexpression simultaneously in all their bladder cancer
patients [27–29]. However, they only categorized the tumors
according to DAKO scores and did not report the exact per-
centage and distribution of positive tumor cells. We noted a
strong complete membranous immunoreactivity for HER2 in
77 % of our HER2 amplified tumors. Importantly, most of
these tumors showed this staining in virtually all neoplastic
cells; only two cases had a partial tumor staining of 60 and
50 % of the tumor cells. This suggests that HER2 overexpres-
sionmostly occurs as an early event in tumorigenesis and only
rarely in subsequent tumor development. Further evidence for
early HER2 overexpression in tumorigenesis was noted in the
two patients with residual urothelial carcinoma in situ which
were strongly HER2 positive (score 3+). Interestingly, even
though our HER2 amplified group presented with marked
heterogeneous morphology, this observation was not reflected
in the HER2 expression pattern. There was no HER2 expres-
sion difference between the morphologically diverse compo-
nents of these tumors; in particular, the micropapillary areas
did not show a more pronounced immunoreactivity than the
other histological components. Notably, 23 % of our HER2
amplified tumorswere immunohistochemicallyHER2 negative.
Similarly, high rates of “false negative” UBC (20–24 %) have
been reported by others [30, 29] and were attributed to puta-
tive fixation artifacts. Therefore, we specifically investigated
HER2 expression intensity along the gradient of diffusion of
formalin from the superficial bladder wall to deeper parts.
However, there were no increments in staining intensities to
be found.
Finally, we tested all UBC for activating HER2 mutations
which have been reported in a small subset of lung and breast
cancer [19, 31, 32]. Interestingly, we detected a D769N mu-
tation in a HER2 amplified tumor sample. To our knowledge,
this mutation has not been described so far, also not in the
series of Ross et al who tested 15 micropapillary UBC for
mutations [33]. However, two mutations, D769H and
D769Y, occurring at the same amino acid position were de-
scribed in breast cancer [31]. Both mutations conferred con-
stitutive activity of the HER2 kinase. Cell lines bearing these
mutations revealed increased HER2, EGFR, and PLCγ phos-
phorylation and had more rapid tumor growth in xenograft
models compared to the wild type control. In addition, both
mutations conferred sensitivity to the HER2 inhibitor lapatinib
[31]. The authors suggested that activation of HER2 by these
mutations may be due to loss of the acidic side chain at D769,
or alternatively, due to an aromatic ring introduced by histi-
dine or tyrosine, respectively. Asparagine and tyrosine can
often been substituted without affecting protein function since
both amino acids contain uncharged polar side chains. If
D769N mutation, like D769Y mutation, induces HER2 activ-
ity, has to be confirmed experimentally.
In conclusion, the aggressive HER2 amplified subtype of
UBC shows specific histomorphological features—frequent
micropapillary architecture, morphological heterogeneity,
and marked tumor-associated chronic inflammation—that
may allow identifying them with high accuracy.
Approximately three-quarters of these tumors overexpress
HER2 strongly. This is promising for targeted anti-HER2
therapies.
Fig. 6 D769N (c.2305G>A) mutation in Exon 19 of the HER2 gene
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